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Wntless/GPR177 functions as WNT ligand carrier protein and 
activator of WNT/-catenin signaling, however, its molecular 
role in gastric cancer (GC) has remained elusive. We 
investigated the role of GPR177 in gastric tumorigenesis and 
provided the therapeutic potential of a clinical development of 
anti-GPR177 monoclonal antibodies. GPR177 mRNA expression 
was assessed in GC transcriptome data sets (GSE15459, n = 
184; GSE66229, n = 300); protein expression was assessed in 
independent patient tumor tissues (Yonsei TMA, n = 909). 
GPR177 expression were associated with unfavorable prognosis 
[log-rank test, GSE15459 (P = 0.00736), GSE66229 (P = 
0.0142), and Yonsei TMA (P = 0.0334)] and identified as an 
independent risk predictor of clinical outcomes: GSE15459 
[hazard ratio (HR) 1.731 (95% confidence interval; CI; 1.103- 
2.715), P = 0.017], GSE66229 [HR 1.54 (95% CI, 1.10-2.151), 
P = 0.011], and Yonsei TMA [HR 1.254 (95% CI, 1.049- 
1.500), P = 0.013]. Either antibody treatment or GPR177 
knockdown suppressed proliferation of GC cells and sensitized 
cells to apoptosis. And also inhibition of GPR177 suppresses in 
vitro and in vivo tumorogenesis in GC cells and inhibits 
WNT/-catenin signaling. Finally, targeting and inhibition of 
GPR177 with antibody suppressed tumorigenesis in PDX 
model. Together, these results suggest GPR177 as a novel 
candidate for prognostic marker as well as a promising target for 
treatment of GC patients. [BMB Reports 2018; 51(5): 255-260]
INTRODUCTION
Gastric cancer (GC) is one of the most common malignancies 
and the third leading cause of cancer death worldwide (1). 
Many studies have attempted to elucidate the molecular 
mechanisms underlying gastric tumorigenesis and develop 
novel molecular targeted therapeutics (2, 3). Recently, 
anti-HER2 receptor and anti-VEGFR2 receptor antibodies were 
developed and approved as targeted therapy for GC patients 
(4-6); however, identification and validation of more candidate 
therapeutic targets are still required (7). 
Dysregulation of WNT/-catenin signaling is commonly 
observed in cancer, including GC (8-10). When WNT ligands 
are secreted and interact with their cognate receptors, 
-catenin–dependent or –independent signaling cascades are 
transduced, resulting in cancer progression. In the absence of 
WNT ligand, -catenin is maintained at a low level through 
degradation by the -catenin destruction complex. Secreted 
WNT ligand binds to FZD-LRP receptors, triggering the 
WNT/-catenin axis. As a consequence, AXIN complexes with 
DVL which inhibits -TrCP to degrade beta catenin, resulting 
in cytoplasmic accumulation of -catenin, which then 
translocates into the nucleus where it binds to the TCF/LEF 
transcription complex, activating target genes transcription 
(11). In many types of cancer, mutations in CTNNB1, AXIN, 
and APC cause hyperactivation of WNT/-catenin signaling, 
resulting in cancer progression even in the absence of WNT 
ligand stimulation. Therefore, various small molecules and 
antibodies are under development as cancer therapeutics. A 
recent report suggests that blocking of WNT secretion may be 
a useful means of treating colorectal cancer (12, 13). 
WNTs are secreted as glycosylated/lipid-modified proteins, 
mediated by the seven-pass transmembrane protein 
Wntless/GPR177 (14-16). GPR177 localizes to compartments 
of the secretory pathway, including the ER, Golgi apparatus, 
endosomes, and plasma membrane. GPR177 is overexpressed 
in several cancer types, and GPR177 knockdown reduced 
cancer formation in a WNT-dependent manner (17). Growth 
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Fig. 1. Clinical impact of GPR177 in gastric cancer (GC) patients. 
(A-D) GPR177 expression correlates with poor prognosis in 
human GC patients. (A and B) Correlation of GPR177 (WLS) 
mRNA expression with overall survival for patients (A, n = 184; 
B, n = 300). Solid and broken lines denote patients whose 
tumors expressed lower and higher levels, respectively, than the 
median value. (C) Micrographs of immunohistochemical staining 
of GPR177 in human GC tumor samples. Representative images 
of negative (left) and positive (right) staining. Scale bar, 100 m. 
(D) Kaplan-Meier analysis of overall survival in a data set of 909 
GC samples used in immunohistochemical analysis and classified 
as having positive (broken line) or negative (solid line) GPR177 
expression.
Fig. 2. GPR177 co-localizes with WNT1 in GC cell lines. (A) 
Schematic diagram of GPR177 structure and function. Upper: 
linear representation of GPR177. Lower: GPR177, with WNT 
cargo, spanning plasma membrane. The seven transmembrane 
domains consist of amino acids 233-252, 265-287, 302-319, 
332-354, 379-401, 434-456, and 471-493. (B) AGS cell lysates 
were loaded and analyzed with GPR177 antibody in western blot 
with or without blocking peptide. Endogenous GPR177 was not 
detected in blocking peptide treated condition. (C) Validation of 
siRNA specific for GPR177. AGS cells were were transiently 
transfected with siRNA as indicated. Full-length blots merged with 
protein size markers are presented in Supplementary Fig. 3. (D) 
AGS cells were stained with GPR177 antibody with or without 
blocking peptide. (E) AGS cells were transiently expressed with 
HA-WNT1 and stained with anti-HA (red) and anti-GPR177 
(green). Overexpression of WNT1 induced GPR177 expression. (F) 
WNT1 and GPR177 were co-localized. Images were processed 
using Carl Zeiss ZEN software.
of colon cancer cells harboring the -catenin active mutant or 
APC mutant was inhibited in a GPR177-dependent manner. 
Thus, these studies suggest that blockade of GPR177 function 
may be a promising therapeutic target (13, 18-20). 
Here, we demonstrate that overexpression of GPR177 
mRNA and protein correlates with poor prognosis of GC 
patients. WNT secretion and cell proliferation were inhibited 
by either anti-GPR177 monoclonal antibody treatment or 
GPR177 knockdown. Moreover, anti-GPR177 antibody 
exhibited anticancer efficacy in mouse and patient-derived 
xenograft (PDX) models. 
RESULTS
GPR177 overexpression in GC is correlated with poor 
survival
To investigate the clinical significance of GPR177 in GC, we 
analyzed publicly available tumor transcriptome data sets and 
found that GPR177 mRNA level strongly correlated with poor 
overall survival in patients with GC (Fig. 1A and B). To 
evaluate whether GPR177 mRNA level correlates with protein 
level while maintaining the clinical implications, we analyzed 
GPR177 protein expression in tissue microarrays (TMAs) 
prepared using tissue of GC patients (n = 909) and a 
monoclonal antibody generated for this study (Fig. 1C and 
Supplementary Table 1). Patient age and sex, tumor histology, 
Lauren classification, and pathological tumor-node-metastasis 
(TNM) stage were analyzed as clinicopathological parameters 
in relation to GPR177 expression level. Intriguingly, all clinical 
and histological parameters were comparable between 
GPR177-negative (n = 463) and GPR177-positive (n = 446) 
GC patients, with the exception of tumor histology 
(Supplementary Table 1). In general, undifferentiated GC 
histology would correlate with unfavorable clinical outcomes; 
however, GPR177-positive tumors were significantly 
correlated with more highly differentiated histological 
subtypes, signifying that GPR177 expression may be 
independently associated with poor clinical outcomes. Indeed, 
positive GPR177 protein expression correlated significantly 
with poorer prognosis of GC patients (Fig. 1D). Furthermore, 
GPR177 expression at both the mRNA and protein levels was 
identified as an independent risk predictor of clinical outcome 
of GC patients even after adjusting the covariates as Lauren 
and TNM stages (Supplementary Table 2). Together, the 
clinical data suggest that GPR177 expression may be a reliable 
and legitimate predictor of unfavorable clinical outcome of GC 
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Fig. 3. GPR177 monoclonal antibody treatment inhibits WNT- 
secretion and viability of gastric cancer cells. (A) GPR177 mRNA 
expression was measured by qPCR. GC cell lines (AGS, MKN25, 
YCC6, YCC7, and YCC16) and 293FT cells were collected and 
analyzed. GC cells showed expression levels similar to that of 
293FT cells. (B) ELISA detection of secreted HA-WNT1. WNT 
secretion was reduced by monoclonal antibody treatment. *P ＜
0.05. (C) GPR177 monoclonal antibody treatment reduced cell 
viability. AGS, YCC6 and YCC7 were treated with GPR177 
monoclonal antibody at the indicated concentration for 24 h. 
Cells showed reduced viability with antibody treatment. (D) AGS 
cells were treated with monoclonal antibody at the indicated 
concentrations and for 24 hr to determine lethal dose (LD)50. 
Viability was assessed by MTT assay. *P ＜ 0.05. (E) Monoclonal 
antibody treatment reduced cell migration. AGS cells transiently 
overexpressing WNT and control cells were seeded on transwell 
plates, and migrated cells were counted. GPR177 monoclonal 
antibody suppressed cell migration (concentration 1 g/ml). *P ＜
0.05. (F) WNT-secreting AGS and YCC6 cells were seeded at 
60-mm dish and treated with monoclonal antibody. Colonies were 
fixed and stained with crystal violet and counted under 
microscope. *P ＜ 0.05. (G) YCC6 and MKN45 cells were treated
with 5 pmol GPR177 siRNA for 48 h or antibody. Apoptosis was 
assayed by FACS. (H) MKN74 and NI3-3 cells were treated with 
2 or 4 g/ml monoclonal antibody for 24 h. Suppression was 
observed only in NI3-3 cells. *P ＜ 0.05. (I) qPCR analysis 
showed that WNT/-catenin signaling is upregulated in NI3-3 cells 
compared to MKN74 cells. GPR177 (WLS), AXIN2, and cyclin D1 
(CCND1) mRNA levels were detected.
patients, evidence that further investigation of molecular 
mechanisms in GC tumorigenesis is warranted.
Both GPR177-mediated WNT secretion and proliferation of 
GC cells are inhibited by anti-GPR177 monoclonal antibody 
GPR177 binds cytoplasmic WNT ligand and secretes it into 
the extracellular milieu. GPR177 domains and their functions 
are described in Fig. 2A. To analyze its biological function in 
GC cell lines, we raised monoclonal antibodies that recognize 
the WNT-binding motif of GPR177. Antibodies were raised 
against each of five antigens. The monoclonal antibodies 
raised against antigen 3 (antibody #3) and antigen 4 (antibody 
#4) were selected and specificity was verified by western 
analysis with GPR177 blocking peptide and knockdown AGS 
cells (Fig. 2B and C). And also, GPR177 localization was 
assessed by immnunocytochemistry with generated antibody 
and the specificity for the antibody was confirmed by blocking 
peptide (Fig. 2D). Notably, GPR177 was co-localized and was 
increased with WNT1 expression as precedent report (Fig. 2E 
and F) (14). 
Considering heterogeneity of GC, we evaluated GPR177 
expression levels in several GC cell lines using qPCR. GPR177 
expression levels showed a certain degree of variation across 
cell lines which are AGS, MKN45, YCC6, YCC7, YCC16 and 
293FT as positive control for WNT-secreting cells (Fig. 3A). 
Next, we examined the possibility that GPR177 is required for 
WNT secretion from GC cells. GC cells transiently expressing 
HA-tagged WNT1 were cultured with or without anti-GPR177 
antibody (Fig. 3B). Levels of WNT ligand in medium were 
assessed by anti-HA ELISA. All cell lines secreted WNT ligand, 
and secretion was inhibited by treatment with anti-GPR177 
antibody. Based on these observations, we found that 
anti-GPR177 antibody efficiently blocks a WNT-secretory 
function of GPR177. We also observed that viability of 
WNT-secreting cells was suppressed by anti-GPR177 antibody 
in a concentration-dependent manner (Fig. 3C and D). 
Whereas WNT overexpression increased the migration of AGS 
cells compared with control cells, and this effect was reversed 
by monoclonal antibody treatment (Fig. 3E). Similar results 
were observed using a colony-forming assay (Fig. 3F). Since 
we observed the inhibitory activity of anti-GPR177 antibody 
on the proliferation gastric cancer cells, we next assessed the 
change of apoptosis in gastric cancer cells with or without 
anti-GPR177. Anti-GPR177 antibody treatment dramatically 
increased the annexin V-positive cells in both YCC6 and 
MKN45 cells, which were again verified with knocking-down 
of GPR177 (Fig. 3G). 
It has been reported that MKN74 cells are capable of brain 
metastasis upon injection into mouse heart, and the brain 
metastatic (NI3-3) cells have been established in cell culture 
(21). NI3-3 cells are sensitive to anti-GPR177 antibody 
treatment compared with the parental MKN74 cells (Fig. 3H) 
and expressed high levels of GPR177 (WLS), AXIN2, and 
cyclin D1 (CCND1) mRNA (Fig. 3I) which are the main targets 
for the WNT/-catenin pathway. Taken together, WNT 
secretion and viability of gastric cancer cells are efficiently 
inhibited by treatment with anti-GPR177 monoclonal antibodies. 
Anti-GPR177 antibody treatment suppresses gastric 
tumorigenesis in vivo
To evaluate in vivo efficacy of anti-GPR177 monoclonal 
antibodies, MKN45 cells were injected into nude mice (n = 5 
each). After two weeks of injection, anti-GPR177 antibodies 
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Fig. 4. GPR177 monoclonal antibody inhibits tumor growth in 
GC xenograft and human PDX model. (A) Nude BALB/C mice 
were injected subcutaneously with 105 MKN45 cells. Two weeks 
later, mice were randomly divided into two groups of 10 mice 
each. One group was intravenously injected with anti-GPR177 
monoclonal antibody #3 ten times over 3 weeks, approximately 
every 2 days. Control group was injected with vehicle PBS. 
Tumor size was measured with calipers. At the end of anti-tumor 
efficacy test, the mice were scarified, and then tumors dissected 
and weighted. (B) Parental MKN45 (pMKN45) and metabolic–
stress-selected MKN45 (sMKN45) cells (105) were subcutaneously
injected into nude mice. Two weeks later, mice were randomly 
divided into two groups of 5 each in both cells. One group was 
intravenously injected with anti-GPR177 monoclonal antibody #3 
eight times over 3 weeks, and the other was treated with vehicle 
PBS. sMKN45 cells were also significantly inhibited by antibody 
treatment. P = 0.0023 for monoclonal antibody #3 in tumor 
weight. (C) Metabolic stress induces GPR177 in sMKN45 cells. 
GPR177 mRNA levels in pMKN45 and sMKN45 cells were 
determined by qPCR. Monoclonal antibody treatment (2 g/ml for 
24 h) reduced sMKN45 cell viability to a greater extent than 
pMKN45 cell viability determined by MTT assay. *P ＜ 0.05. (D) 
Stable shRNA-mediated knockdown of GPR177 in AGS cells. 
Control cells were treated with non-targeting shRNA. Cells were 
subcutaneously injected into nude mice. Tumors were measured 2 
weeks later with calipers every 2 days. *P ＜ 0.05. (E) Represen-
tative cases of PDX models according to GPR177 expression 
levels. GPR177 expression was detected by immunohistochemistry 
using anti-GPR177 antibody #3. (F) Summary of PDX models by 
GPR177 expressions. Cases were classified based on GPR177 
expression level as high, moderate, low and negative expression. 
(G) GA083 tumors were transplanted to athymic nude mice and 
treated either with anti-GPR177 monoclonal antibody #3 eight 
times over 3 weeks (n = 10) or with vehicle PBS (n = 10). (H) 
Tumor weight of dissected tumors in C).
were delivered intravenously every 2 days for 3 weeks, and 
tumor size was measured. Treatment with anti-GPR177 
antibodies reduced tumor growth significantly (Fig. 4A). Upon 
completion of experiments, tumors were removed from mice 
and further analyzed by western blotting. Intriguingly, we 
found that the WNT/-catenin signaling pathway was 
upregulated in xenograft tumors compared to the parental 
MKN45 cells (Supplementary Fig. 1A). We hypothesized that 
this might be the result of selective evolutionary pressure 
imposed by the tumor environment, favoring stress-resistant 
molecular traits. Concordant with this, it has recently been 
reported that metabolic stress induces stem-like pheno-
conversion through the WNT pathway (22). To confirm this, 
we generated metabolic–stress-selected MKN45 (sMKN45) cell 
lines as previously reported. Compared to parental MKN45 
lines, sMKN45 cells showed a more aggressive tumor-forming 
phenotype (Supplementary Fig. 1B). Next, sMKN45 cells were 
subcutaneously injected into nude mice to establish 
xenografts. Treatment with anti-GPR177 antibody substantially 
reduced tumor progression in terms of both volume and 
weight (Fig. 4B). The sMKN45 cells showed increased 
GPR177 expression and sensitivity to anti-GPR177 antibody in 
vitro (Fig. 4C). Previous studies have clearly demonstrated that 
loss of GPR177 function in other types of cancer suppresses 
tumor formation in xenograft models (8, 13, 18). Therefore, we 
tested whether GPR177 knockdown in GC cancer would 
inhibit tumor formation. Using shRNA targeting GPR177 
(shGPR177), we generated AGS cell lines that stably express 
low levels of GPR177 mRNA and protein. Control (shCON) 
and stable shGPR177 AGS cells were subcutaneously injected 
into BALB/C nude mice (n = 5 mice/group). Two weeks later, 
xenograft tumors were measured with a caliper every 2 days 
and terminated when volume exceeded 800 mm3. Compared 
to control cells, shGPR177-expressing AGS cells showed 
retarded growth rate (Fig. 4D). These data collectively show 
that targeted inhibition of GPR177 suppresses in vivo 
tumorigenesis of gastric cancer cells.
Anti-GPR177 antibody treatment suppresses gastric 
tumorigenesis in PDX model
Previously, we established GC patient-derived xenograft (PDX) 
model which could be applied to predict cancer patient's 
responses to the cancer drug (23). We tested whether this 
tumor suppression would be reproducible in a PDX model. 
Among GC patients who had undergone gastrectomy, GPR177 
expression level of tumor specimens was determined by 
immunohistochemistry and designated high, moderate, low or 
negative (Fig. 4E and F). Case GA083, a GPR177 high 
expressing model, was expanded and divided randomly into 
two groups. One group was injected intravenously with 
anti-GPR177 monoclonal antibody #3 every 2 days for 3 
weeks, and the other group was injected with PBS as negative 
control. Tumor size was measured every 2 days (Fig. 4G). Both 
tumor size and weight were significantly reduced in antibody 
treatment group compared with control group (Fig. 4G and H). 
Taken together, these data show that targeted inhibition of 
GPR177 suppresses human gastric tumorigenesis.
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DISCUSSION
GPR177 is seven-pass transmembrane protein that binds 
cytoplasmic WNT ligand and secretes it to the extracellular 
space (24). Dysregulation of WNT secretion and uncontrolled 
activation of the WNT/-catenin signaling pathway is 
associated with disease, such as cancer, and developmental 
abnormalities (25-29). GPR177 knockout results in WNT 
loss-of-function phenotypes in species ranging from 
Drosophila to Mus musculus. In cancer, GPR177 upregulation 
enhances tumor progression, and downregulation has been 
proposed as a potential therapeutic target. 
Previous studies have shown that inhibition of GPR177 
expression efficiently suppresses cancer progression (8, 13, 
18). The cancer-promoting activity of GPR177 has been 
explained in positive upregulation of the WNT/-catenin signal 
in most cancer types. In this study, we found that GPR177 is 
required in WNT/-catenin, signaling in GC cells.
We examined the role of GPR177 in the WNT-secreting 
pathway in GC cell lines. We expressed exogenous WNT1 
ligand and confirmed that WNT was secreted into the culture 
medium. To prevent WNT secretion, we treated GC cells with 
anti-GPR177 monoclonal antibody. Because the antibodies 
were raised against the middle of the WNT-binding motif, we 
presumed that they would block this function of GPR177. 
Antibody treatment reduced not only WNT secretion but also 
cell viability and migration. As antibody treatment was 
effective only on WNT-secreting cells, we speculated that, 
whereas expression level is important for cancer cell prolifera-
tion, the presence of intact WNT-secretory machinery, 
including the ER, Golgi, and cargo carrier systems, was likely a 
more critical factor in the case of antibody treatment of GC. 
Thus, we concluded that GC cell lines that secrete WNT 
ligand are sensitive to monoclonal antibody treatment in vitro.
As a positive component of the WNT/-catenin signaling 
pathway, GPR177 is upregulated when the signal is activated. 
More precisely, -catenin, which is stabilized and dissociated 
from the destructive complex, is translocated into the nucleus 
and transcriptionally activated. Consequently, GPR177 
transcription is induced and mRNA expression increases. 
However, it is still not clear that in this mode of positive 
feedback regulation, a cell is induced to produce more WNT 
ligand in an autocrine manner. Regardless of whether WNT 
ligand synthesis is induced in a WNT–ligand-dependent or 
–independent manner, increased GPR177 expression is 
followed by induction of WNT/-catenin signaling. 
Furthermore, we confirm that inhibition of GPR177 function 
effectively suppressed tumor progression in in vivo xenograft 
and PDX models. GC patients who are expressing high levels 
of GPR177 thereafter capable of WNT secretion could be 
tested whether the treatment of GPR177 antibody will 
suppress tumor progression. From clinical perspective, if we 
use the PDX model and personalized molecular information, 
we can stratify GC patients according to WNT-secretion 
proficiency and predict the therapeutic outcome of anti-GPR177 
monoclonal antibody treatment as a novel therapy as 
described in Supplementary Fig. 2.
In conclusion, we report for the first time that GPR177 is 
highly expressed in GC patients and that GPR177 expression 
level is positively correlated with poor patient prognosis. 
Further, our findings provide a rationale of GPR177 inhibition 
as a therapeutic target for GC treatment.
MATERIALS AND METHODS
Cell culture
Cell lines were maintained in RPMI-1640 supplemented with 
10% heat-inactivated fetal bovine serum and 1% penicillin/ 
streptomycin. 293FT and YCC cells were maintained in 
DMEM as previously described (30).
Statistical analysis
Prognosis was evaluated by overall survival, from day of 
surgery to death by any cause. Correlation of gene expression 
with overall survival was estimated using Kaplan-Meier 
survival plots and log-rank tests. Multivariable Cox proportional 
hazards regression analysis was used to evaluate independent 
prognostic factors associated with overall survival, including 
age, sex, Lauren type, and TNM-stage groups as covariates. A 
two-sided P value ＜0.05 was considered statistically 
significant. All statistical analyses were conducted in the R 
language environment (http://www.r-project.org). 
PDX model
A PDX model was established as previously reported (23). 
Briefly, a tumor was obtained from a surgical specimen (F0) 
immediately after gastrectomy. Formation of a tumor greater 
than 500 mm3 in volume at the implant site was considered a 
successful engraftment in the case of subcutaneous 
implantation. The mouse was anaesthetized, and the tumor 
(F1) was removed for serial transplantation into the next 
generation (F2, F3). Mice were housed and fed according to 
the institutional guidelines for animal care. All animal 
experiments were approved by the Institutional Animal Care 
and Use Committee (IACUC) of the Yonsei University College 
of Medicine (2014-0130). Six-week old female athymic nude 
mice (Japan SLC, Inc., Japan) and male NOG mice 
(NOD/Shi-scid, IL-2 Rnull, Ciea, Japan) were used for each 
PDX model. Before the experiments, the animals were 
acclimated for seven days to a 12 h light/12 h dark cycle. One 
case of a GPR177-positive tumor specimen (F0) that was 
successfully maintained through passages was subcutaneously 
implanted into a NOG mouse (passage 1 or F1). 
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